anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To review the first robotic hernia repairs performed at the Ilyinsky Hospital, evolution of this technology, learning curve and early outcomes.
MATERIAL AND METHODS: There were 17 procedures at the Ilyinskaya Hospital between 2021 and 2023 (13 men and 4 women). Mean age was 60 years, body mass index 28 kg/m2. ASA grade 1 was observed in 1 patient, grade 2 - 14 ones, grade 3 - 2 patients. Ventral, inguinal and umbilical hernias were diagnosed in 7, 8 and 2 cases, respectively. Ventral hernias required IPOM+ procedure in 3 cases, eTEP-RS procedure in 2 cases and eTEP-RS-TAR procedure in 2 cases. Patients with inguinal hernia underwent transabdominal preperitoneal hernia repair. In case of umbilical hernia, TARUP procedure was performed in 1 case and vTAPP procedure in 1 case.
RESULTS: Mean surgery time was 2 hours 38 min (min 1 hour 35 min, max 10 hours 11 min). There was one intraoperative complication (bleeding from epigastric artery). The follow-up period ranged from 3 months to 3 years. There were no recurrent hernias. Postoperative complications were noted in 2 cases. One patient was diagnosed with epididymitis after TAPP, 1 patient - with seroma after eTEP-RS procedure. All complications were relieved by conservative treatment. Bleeding from a. epigastrica inferior was diagnosed after removal of the trocar at the end of surgery. This event required suturing.
CONCLUSION: Robotic hernia repair appears to be technically feasible and safe. This approach provides favorable results regarding quality of life and recurrence rate.
A method, a system, and a computer program product are provided. Electronic health records of patients, indicating encounters with healthcare providers for medical conditions, are analyzed to determine networks of healthcare providers. Based on the analyzing, healthcare provider network data corresponding to a graphical representation of the determined networks of healthcare providers are generated. The healthcare provider network data includes multiple paths, each of which indicates a series of healthcare providers. Based on the generated healthcare provider network data, a path indicating a series of healthcare providers within the healthcare provider network data and corresponding to at least one medical condition indicated by an electronic health record of a patient is identified. An action for the patient and a corresponding healthcare provider to perform the action is determined based on the identified path. An appointment is automatically scheduled for the patient with the corresponding healthcare provider.
The invention encompasses Drosophila Recombination Associated Protein (DRAP) isolated from D. melanogaster and a nucleic acid sequence encoding DRAP. The Drosophila Recombination Associated Protein, its homologues from other organisms or active peptides derived therefrom, as well as DNA encoding such protein are useful for homology-dependent pairing of three DNA strands. The combination of strand-transfer and topoisomerase activities associated with DRAP permits directed pairing and cleavage at defined site(s) within DNA. This in turn makes possible the isolation and/or removal of a defined segment of DNA. DRAP is also useful in cloning, genomic cloning and gene mapping, in promoting gene disruptions or "knockout" mutations, in carrying out targeted mutagenesis of specific genes and in generating transgenic animals. The invention further encompasses a method for experimental and therapeutic application of DRAP driven knockouts or other modifications of genes responsible for genetic diseases as well as the use of DRAP driven genetic manipulation of genes in gene therapy.
Isotonic seawater solution (9 g / L NaCl). The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and presenting neuropsychiatric manifestations ( n  = 98) were offered treatment with m/umPEA 600 mg twice daily for 3 months. Those accepting m/umPEA therapy ( n  = 57) were compared with those who did not ( n  = 41), in terms of depression, fatigue, chronic pain and subjective well-being, through validated scales administered pre- and posttreatment. The two groups did not differ in terms of demographics, comorbidities, psychiatric history, antidepressant therapy, acute COVID-19 severity and baseline neuropsychiatric status. Patients receiving m/umPEA showed a greater improvement in depression and fatigue (both P  < 0.05). Conversely, no association was found with changes in chronic pain or subjective well-being. At multivariable logistic regression, m/umPEA predicted neuropsychiatric improvement independently of age, sex and baseline neuropsychiatric status. Worse pretreatment fatigue and subjective well-being identified those who most likely benefited from treatment. In conclusion, despite its retrospective nature, our study suggests that m/umPEA may improve depression and fatigue in COVID-19 survivors, justifying future research in this setting.
Dosages of barbiturates must be individualized with full knowledge of their particular characteristics. Factors of consideration are the patient’s age, weight, and condition.

Adults—As a hypnotic, 100 mg at bedtime. Preoperatively, 200 to 300 mg 1 to 2 hours before surgery.

Pediatric Patients—Preoperatively, 2 to 6 mg/kg, with a maximum dosage of 100 mg.

Special patient population—Dosage should be reduced in the elderly or debilitated because these patients may be more sensitive to barbiturates. Dosage should be reduced for patients with impaired renal function or hepatic disease.
MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
The present invention relates to natural killer cell-specific chimeric antigen receptor (NK-CAR), etc. which are completed by confirming that NK-CAR, which contains a specific combination of domains derived from a natural killer cell-specific activation receptor, can effectively activate natural killer cells and enhance a killing ability for target cells. Specifically, the present inventors produce three natural killer cell-specific CARs composed of a combination of specific domains. In addition, it is confirmed that according to natural killer cells expressing the NK-CAR, the production of cytokine and granzyme B or the activation of AKT and ERK in response to target cells are further enhanced and degranulation is promoted, and superior apoptosis activity is exhibited. The NK-CAR according to the present invention can strongly induce the activation of natural killer cells and enhance apoptosis activity to be used as an immunotherapy for treatment of various diseases including cancer. In particular, CAR-based anticancer treatment using the natural killer cells does not cause cytokine release syndrome or neurotoxicity, and has fewer side effects than CAR-T since autologous and allogeneic natural killer cells can be used. Accordingly, the natural killer cells expressing the NK-CAR according to the present invention can be used as a cell therapy agent with reduced side effects and maximized disease treatment effects. The chimeric antigen receptor is expressed in the natural killer cells.
The present invention teaches a new and innovative pharmaceutical composition and method for the treatment of age-related macular degeneration in a patient in need thereof. In particular, the present invention teaches the administration of artemisone for the treatment and/or prevention of AMD in a patient in need thereof. This invention relates to one certain extract of the Artemisia annua plant, both in its crude and refined form composed substantially of Artemisone, a compound that is chemically classified as a sesquiterpene with an endo-peroxide group [FIG.  1 ]. The present invention teaches a for the treatment of either wet or dry age-related macular degeneration. The invention provides for an initial treatment using an intravitreal injection of Artemisone followed by the use of an oral dosage form which is designed to maintain the therapeutic concentration of Artemisone in the eye without having to perform constant intravitreal injections into the eye.
Dentifrice compositions comprise an enamel-solubility-reducing material comprising:  (a) a water-soluble fluoride salt providing at least 25 p.p.m. of the dentrifrice of fluoride ions, the total amount of ionized and anionized fluorine not exceeding 4000 p.p.m. p  (b) Stannous tin in the form of a water-soluble salt providing a total content of stannous tin in solution of from 5000 to 15 000 p.p.m. (c) a water-soluble source of six-carbon aldonate groups capable of forming water-soluble chemical complexes with stannous tin, the molar ratio of aldenate-groups to stannous tin being in the range 1:1 to 3:1, the molar ratio of stannous tin to fluoride ions being greater than 1:1 and the dentifrice having a pH of from 5-7 when measured by a specified procedure.  Specified fluoride salts are stannous, sodium and potassium fluorides (Prepared), indium, palladium, ferrous and lithium fluorides and water soluble complex salts e.g. fluo-silicates, -zirconates, -stannites, -borates and -titanates. Specified stannous salts are aldonates and stannous fluoride (preferred), stannous mixed halides, and stannous sulphate.  Suitable aldonates are the gluconate group, i.e. such compounds as gluconic acid, gluconates and glucono-lactone and other six-carbon aldonates of the D and L series.  The dentifrices may contain conventional abrasives especially condensed phosphates, forming agents, thickeners, flavours, colours and humectants.
Nitroglycerin is contraindicated in patients who are allergic to it. Allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. 

Do not use NITRO-DUR in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. Concomitant use can cause severe drops in blood pressure.   
Do not use NITRO-DUR in patients who are taking the soluble guanylate cyclase stimulator riociguat. Concomitant use can cause hypotension.
Because of the anticoagulant effect of protamine, it is unwise to give more than 50 mg over a short period unless a larger dose is clearly needed .

Patients with a history of allergy to fish may develop hypersensitivity reactions to protamine, although to date no relationship has been established between allergic reactions to protamine and fish allergy.

Previous exposure to protamine can induce a humoral immune response and predispose susceptible individuals to the development of untoward reactions from the subsequent use of this drug. Patients exposed to protamine through the use of protamine-containing insulin or during heparin neutralization may experience life-threatening reactions and fatal anaphylaxis upon receiving large doses of protamine intravenously. Severe reactions to intravenous protamine can occur in the absence of local or systemic allergic reactions to subcutaneous injection of protamine-containing insulin. Reports of the presence of antiprotamine antibodies in the sera of infertile or vasectomized men suggest that some of these individuals may react to the use of protamine sulfate.

Fatal anaphylaxis has been reported in one patient with no prior history of allergies.
Half of those living with HIV in the United States are over 50 years of age. As people living with HIV (PWH) live longer with the disease, the tradeoff is that they live with multiple comorbidities. One of the more common comorbidities is depression. There is a need to find innovative and accessible nonpharmacological interventions that can help older people living with HIV/AIDS to manage depressive symptoms that may also affect their treatment outcomes. Tai chi/Qigong (TCQ) is a series of slow, low-impact meditative movements that integrate breath work, meditation, and stances; and may improve depressive symptoms. Investigators propose testing the efficacy of a remotely delivered standardized TCQ intervention that has shown to be acceptable and feasible with a population of older people living with HIV/AIDS. Thus, this study proposes three aims: (i) to determine whether a remotely delivered TCQ intervention is directly efficacious in improving depressive symptoms compared to a health education control group among older PWH (50 years of age or older); (ii) to determine whether a remotely delivered TCQ intervention indirectly improves depressive symptoms via biological, psychological, and behavioral mechanisms compared to a health education control group among older PWH and (iii) to determine whether the direct and indirect associations between a TCQ intervention and depressive symptoms is moderated by gender among older PWH. Participants (n=326) will be recruited using social media sites (e.g., WebMD, google, Facebook) throughout the United States. All assessments will be conducted via Zoom videoconferencing or phone. Participants will be randomized to 1 of 2 conditions: the TCQ intervention, or a health education control group condition. Both the TCQ and the health education control condition will be delivered via Zoom to participants in the form of live, synchronous classes. Investigators will assess the efficacy of TCQ by looking at instruments that measure depression; and potential mechanisms such as sleep, fatigue, emotional regulation, and heart variability at baseline, 3-month, and 9-month post-intervention. Blood will also be collected at baseline and at 9-month to collect viral load and an inflammatory marker (C-reactive protein). Data will be described using descriptive techniques.
PROBLEM TO BE SOLVED: To obtain a gray hair preventing and curing agent containing a compound having an excellent melanine-production accerelating effect as effective ingredient by containing kaempferol glycoside. SOLUTION: This accelerating agent for producing melanine contains kaempferol-3-glycoside (astragalin). Astragalin is one of glycosides of kaempferol, expressed by the formula and capable of being synthesized by a known method but a plant originated one may be preferable. As the plant, leaves of persimmon, Hydrangea serrata, Gymnema sylvestre R. Br., guava, Lycium chinese, Sasa albo-marginata, jasmin, Equisetum arvense, Houttuynia cordata, Coix ma-yuen, leaves of loquat, green tea, hydrangea tea, etc., are cited. The amount of astragalin to be added is preferably about 0.00001-80 wt.%, esspecially preferably about 0.0001-70 wt.%. The dose is about 0.025-3 mg, preferably about 0.05-1.5 mg/kg body weight/day.
LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
For clinics assigned to mBMI2Kids intervention, Pediatricians will be trained in Motivational Interviewing (MI) and behavioral intervention. Pediatricians will conduct up to 3 sessions with each parent (3 x 10 min) and refer patients electronically to experienced MI-trained lifestyle coaches. With full access to the electronic medical record coaches will call referred families (child's BMI-for-age ≥85th percentile) and deliver a telephonic MI counseling over two years (6 x 45 min) simultaneous with pediatricians. 49 clinics will be selected with 24 participating in the intervention and 25 providing patients with usual care.
Infertile men commonly have difficulty timing sexual relations around the time of ovulation. There is a high incidence of abnormal sperm morphology in infertile men. Omega 3 fats are known to increase the production of nitric oxide, which is the mediator of the male response, and folic acid is an important cofactor in the production of nitric oxide. Omega 3 fats are also important in the structure and function of cell membranes. There is a high incidence of deficient intake of omega 3 fats and folic acid in the U.S. population. Both folic acid and omega 3 fats are available as nutritional supplements and the doses used in this study are doses commonly recommended as nutritional supplements.

Comparison: Omega 3 fats plus folic acid will be compared with placebo plus folic acid in men age 35 to 55 attempting pregnancy with normal or mildly impaired semen quality. They will fill out dietary questionaires, questionaires regarding sexual function, and will have measurements of serum nitrates, blood pressure, and semen quality before and during use of these nutritional supplements. In men continuing on both omega 3 fats and folic acid, we will compare the effects of a sub-therapeutic dose of a PDE 5 inhibitor versus placebo on their sexual function.
The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum participants about health conditions (hypertension, diabetes, and depression), important health behaviors , physical and emotional postpartum symptoms, teach self-management skills, enhance social support, and connect post-partum participants with community resources. The education materials will provide simple actions that participants can utilize to address symptoms, realistic time frames for healing, danger signs to look out for and contact their physicians, and a list of resources for specific issues. The patient navigator will spend approximately 20 minutes with participants after enrollment, in the hospital. Following discharge, the patient navigator will contact each patient between 4 and 20 times, by phone and/or text with a research phone, to address questions and link participants to medical and community resources.
Tablets comprise two layers, both contg. the active ingredient, which is liberated immediately or subsequently. They are made by (a) breaking up a wax of hydrogenated soya oil type in a mill or particle blast to 10 microns; (b) mixing the wax with 0.5-40% dispersing agent of hydroxypropyl cellulose type of low substn. grade, and then with 0.1-30% agglutinant of hydroxypropyl methyl cellulose phthalate or gelatin type, in a mixer at 0-50 deg.C for 1-60 mins.; (c) granulating the mixt. and drying; and (d) compressing the granulates in a rotating plate machine at 1-80 rpm.
Maintaining muscle strength is mandatory for elderly persons to keep autonomy. Resistance exercise increases muscle strength in old and very old subjects, but there seems to be little effect on muscle mass. Citrulline is an amino acid that stimulates muscle protein synthesis, but its effect on muscle strength and mass remains to be determined. The aim of this study is to assess the effect of citrulline supplementation on muscle strength in elderly institutionalized subjects undergoing a resistance exercise training program.

All the subjects (84) will undergo a resistance exercise training program for 12 weeks. The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week. These muscle groups were chosen because of their importance in functional activities. The subjects will be randomized into two groups. An intervention group will receive orally citrulline at 10 g/day, and a control group will receive an isonitrogenous amount of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity). During the 12 weeks of supplementation, clinical tolerance will be evaluated. Strength testing will be repeated every two weeks for 12 weeks. The primary endpoint is the outcome of maximum strength of knee extensor muscles. Fat-free mass (DEXA), gait velocity, timed get up and go, spontaneous physical activity (activity monitors), nutritional status (weight, albuminemia, TRANSTHYRETINEMIA) and quality of life will be measured at inclusion and at the end of the study. The number of falls during the study will be recorded.
This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes (focusing initially on the UGT2B7 enzyme) and tamoxifen (TAM) toxicity. Pre- \& post-menopausal women (aged ≥18 years) taking TAM (20 mg/day) as standard therapy or chemopreventive therapy will be included in this study. Patients will be enrolled after they complete all primary surgery, radiation, and adjuvant chemotherapy. Patients will be excluded if they are undergoing other adjuvant endocrine therapies. Other reasons for exclusion will include patients who are pregnant or lactating, or are currently on corticosteroids, phenobarbital, or megestrol acetate. The goal will be to recruit a total of 45 eligible patients over a 1 year accrual period. The investigators expect to treat \~50 new patients per year with TAM at the standard dose of 20 mg/day.
The composition has excellent taste qualities and can be applied in the form of honey solution, syrups, candies, chewing gums, capsules or tablets. It contains ultrafiltered protein hydrolysate and easily assimilated high-calory containing products. The hydrolysate can be of micro seaweeds or of milk or animal protein and may contain no salts. The high calory content source can be bee honey or laevulose. Applied in patients with chronic renal insufficiency the composition reduces the products of nitrogen retention and in this way disintoxates the organism. In addition it incrases the protein synthesis and increases the haemoglobin and the serum level of the proteins. The composition can also be used in liver impairments of inflammatory, toxic or degenrative origin which reduces the deposition of lipids and products of the lipid peroxidation, and at the same time increases the synthetic function of the liver cells. It also has a general tonization activity and can be used in heavy physical loads. 3 claims
Subjects will be given general educational information consisting of basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The research coordinator (RC) will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that the MUC subjects receive. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
An open label, multi-center, phase 2 study was conducted in patients with MM or NHL who were to be treated with peripheral blood stem cells (PBSC) autologous transplantation. The only change to the standard of care was the addition of plerixafor to a mobilization regimen of chemotherapy and G-CSF. Patients were first given a mobilizing regimen of chemotherapy as per local practice guidelines and G-CSF (at customary doses) and apheresis was performed. After the first apheresis, plerixafor was given at 10PM, 10-11 hours before the second apheresis the next day or in the morning of the second day, 6 hours before the second apheresis. The change in the patient's peripheral CD34+ cell count between the plerixafor dose and the start of apheresis was measured. The apheresis yields on Day 1 and Day 2 were compared.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.